This is a phase IV, prospective biomarker study that will be conducted at Sinai Hospital of
Baltimore. After screening for patients who were treated with aspirin, thirty patients will
be treated with 81 mg enteric coated (EC) aspirin for 7 days in the "lead-in" period and then
will be randomly treated with EC aspirin (81mg qd) or EC aspirin (81mg qd) plus rivaroxaban
(2.5 mg bid) for 12 weeks. Platelet aggregation, soluble markers of platelet activation and
inflammation, thrombin generation kinetics and tissue factor (TF)-induced platelet-fibrin
clot strength will be assessed at baseline (after 7 days of treatment with 81 mg EC aspirin),
and 4 and 12 weeks after randomization of the study drug administration.
Aspirin 81 mg,
Rivaroxaban 2.5 Mg Oral Tablet
Clinical Study Identifier
Last Modified on
21 October 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.